Funds · 13F holdings

First Turn Management, LLC

13F holdings for Q2 2026 · DEL MAR, CA · filed August 14, 2026

First Turn Management, LLC reported $935M in 13F securities across 31 holdings for Q2 2026, in a Form 13F filed August 14, 2026. The largest positions were RVMD (8.3%), ABVX (7.0%), AXSM (5.7%). Reported value rose 4.4% from the quarter before. It opened 6 new positions, added to 13, trimmed 11 and sold out of 8.

13F value Q2 2026
$935M
Holdings
31
Change vs prior quarter
+4.4%
Rank by 13F value
#2,661

Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.

Top holdings

StockValueWeightSharesChange in sharesMove
RVMD Revolution Medicines Inc.$77.8M8.3%415,307-11.3%Trimmed
ABVX Abivax SA$65.3M7.0%489,889+5.2%Added
AXSM Axsome Therapeutics Inc.$53.5M5.7%218,415+15.7%Added
ELVN Enliven Therapeutics Inc.$48.4M5.2%954,360+53.0%Added
BBIO BridgeBio Pharma Inc.$47.2M5.0%633,364-9.0%Trimmed
Roivant Sciences LTD SHS$47.1M5.0%1,331,066+11.8%Added
UTHR United Therapeutics Corporation$46.0M4.9%84,932-18.9%Trimmed
CYTK Cytokinetics Incorporated$44.9M4.8%527,412+85.9%Added
XENE Xenon Pharmaceuticals Inc.$36.2M3.9%600,200-23.7%Trimmed
CELC Celcuity Inc.$34.4M3.7%329,101+56.3%Added
VRDN Viridian Therapeutics Inc.$30.7M3.3%1,670,000+83.2%Added
INSM Insmed Incorporated$28.1M3.0%263,851+6.2%Added
Uniqure NV$28.0M3.0%608,925-1.1%Trimmed
Ascendis Pharma A/S$28.0M3.0%104,877NewNew
PRAX Praxis Precision Medicines Inc.$28.0M3.0%83,528+96.8%Added
DNTH Dianthus Therapeutics Inc.$27.9M3.0%285,771+29.4%Added
PCVX Vaxcyte Inc.$25.8M2.8%443,836NewNew
MIRM Mirum Pharmaceuticals Inc.$25.5M2.7%218,051-45.6%Trimmed
PVLA Palvella Therapeutics Inc.$23.9M2.6%156,450+5.6%Added
COGT Cogent Biosciences Inc.$23.3M2.5%602,281-36.4%Trimmed
ERAS Erasca Inc.$22.4M2.4%1,221,721+40.8%Added
ORIC Oric Pharmaceuticals Inc.$21.8M2.3%2,017,2840%Unchanged
Newamsterdam Pharma Co NV$19.7M2.1%582,497+4.3%Added
Apogee Therapeutics Inc Com$18.4M2.0%138,822-73.0%Trimmed
RYTM Rhythm Pharmaceuticals Inc.$17.1M1.8%154,018NewNew

Share positions only, at the value reported for the end of Q2 2026. Weight is the share of $935M in share positions; options and bonds count in the 13F value but not here.

Biggest buys in Q2 2026

  1. Ascendis Pharma A/S New+$28.0M
  2. PCVX Vaxcyte Inc. New+$25.8M
  3. CYTK Cytokinetics Incorporated Added+$20.8M
  4. RYTM Rhythm Pharmaceuticals Inc. New+$17.1M
  5. ELVN Enliven Therapeutics Inc. Added+$16.8M
  6. INBX Inhibrx Biosciences Inc. New+$15.6M
  7. ORKA Oruka Therapeutics Inc. New+$14.8M
  8. VRDN Viridian Therapeutics Inc. Added+$13.9M
  9. PRAX Praxis Precision Medicines Inc. Added+$13.8M
  10. CELC Celcuity Inc. Added+$12.4M

Biggest sells in Q2 2026

  1. Apogee Therapeutics Inc Com Trimmed-$49.8M
  2. Nuvalent Inc Com Trimmed-$42.5M
  3. IDYA IDEAYA Biosciences Inc. Sold out-$29.1M
  4. MIRM Mirum Pharmaceuticals Inc. Trimmed-$21.4M
  5. Ascendis Pharma A/S Sponsored Sold out-$17.5M
  6. KYMR Kymera Therapeutics Inc. Trimmed-$17.4M
  7. FULC Fulcrum Therapeutics Inc. Sold out-$17.3M
  8. Terns Pharmaceuticals Inc Sold out-$17.2M
  9. VERA Vera Therapeutics Inc. Sold out-$17.0M
  10. NTRA Natera Inc. Sold out-$16.2M

The change in shares since Q1 2026, adjusted for stock splits and priced at the Q2 2026 value per share. 6 new, 13 added, 11 trimmed, 8 sold out.

Sector mix

13F value by quarter

Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
Q3 '25
Q4 '25
Q1 '26
Q2 '26
Reported 13F value: Q1 2024 $668M, Q2 2024 $615M, Q3 2024 $632M, Q4 2024 $558M, Q1 2025 $496M, Q2 2025 $536M, Q3 2025 $666M, Q4 2025 $875M, Q1 2026 $895M, Q2 2026 $935M.

More holdings

StockValueWeightSharesChange in sharesMove
INBX Inhibrx Biosciences Inc.$15.6M1.7%164,783NewNew
SRRK Scholar Rock Holding Corporation$14.9M1.6%271,227-39.2%Trimmed
ORKA Oruka Therapeutics Inc.$14.8M1.6%155,343NewNew
KYMR Kymera Therapeutics Inc.$11.8M1.3%102,533-59.7%Trimmed
SION Sionna Therapeutics Inc.$4.9M0.5%110,493NewNew
Nuvalent Inc Com$3.2M0.3%26,298-92.9%Trimmed

Questions about First Turn Management, LLC

What does First Turn Management, LLC own?
In its Form 13F for Q2 2026, First Turn Management, LLC reported 31 holdings worth $935M. The five largest were RVMD, ABVX, AXSM, ELVN, BBIO.
What did First Turn Management, LLC buy and sell in Q2 2026?
First Turn Management, LLC opened 6 new positions, added to 13, trimmed 11 and sold out of 8 compared with the quarter before.
When did First Turn Management, LLC file its latest 13F?
Form 13F is due 45 days after each quarter ends. The Q2 2026 report was due August 14, 2026 and was filed August 14, 2026.

From Form 13F filed by First Turn Management, LLC (SEC CIK 0001993440) for the quarter ended June 30, 2026, via the SEC's Form 13F data sets. Amendments that restate a report replace it; amendments that add holdings are included. View on SEC EDGAR · All funds · Get this as JSON